Crossref
Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer’s drug
BMJ · 2024
DOI: 10.1136/bmj.q2010 ↗Kurz gefasst
Fachartikel in der Zeitschrift BMJ, 2024. Verfasst von Jeanne Lenzer und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Alzheimer Disease, Conflict of Interest, United States Food and Drug Administration, Drug Approval. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Alzheimer DiseaseConflict of InterestUnited States Food and Drug AdministrationDrug ApprovalHumansUnited StatesAntibodies, Monoclonal, HumanizedDrug Industry
Substanzen
Antibodies, Monoclonal, Humanizedaducanumabdonanemab
Zitieren
APA
Lenzer, J., & Brownlee, S. (2024). Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer’s drug. BMJ. https://doi.org/10.1136/bmj.q2010
Vancouver
Lenzer J, Brownlee S. Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer’s drug. BMJ. 2024. doi:10.1136/bmj.q2010
BibTeX
@article{Lenzer2024,
author = {Lenzer, Jeanne and Brownlee, Shannon},
title = {Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer’s drug},
journal = {BMJ},
year = {2024},
doi = {10.1136/bmj.q2010}
}
EUVIMED